Webinar Summary/Description
Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths for U.S. women, yet it has the highest mortality rate amongst gynaecological cancers. Lack of symptoms as well as the deficiency of highly specific biomarkers has resulted in only a quarter of OC cases being diagnosed at FIGO stage I. An effective screening strategy for early diagnosis would be particularly advantageous since 5-year survival rates can be as high as 90%.
In this webinar, Professor Facundo Fernandez will discuss the methodology used to study the feasibility of mass spectrometry (MS) metabolome-based OC detection. The results from three cancer research studies will be shared. Employing 2-dimensional MS imaging on ovarian tissues confirmed the source of biomarkers detected in sera and provided further insight into the biological pathways involved in tumour development. Overall, these results demonstrated that serum metabolites may be useful for detecting early-stage OC and supports conducting studies with larger cohorts.
In this webinar you will learn:
- About a methodology to study the feasibility of mass spectrometry (MS) metabolome-based ovarian cancer detection
- How 2-dimensional MS Imaging can be used to confirm the sources of biomarkers and provide further insight into the biological pathways involved in tumour development
- How serum metabolites may be useful for detecting early-stage cancers
Who should attend:
- Cancer researchers
- Researchers doing mass spectrometry
- Translational medicine researchers
- Cell Biologists and Biomarker researchers